Osteosarcoma
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
CLINVAR |
|
|
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
HPO |
|
|
|
Osteosarcoma
|
1.000 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
MGD |
|
|
|
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
1847-1857) develop a new mouse model of osteosarcoma in which a GOF mutant p53 allele is expressed specifically in osteoblasts, while the tumor microenvironment remains wild type for p53, allowing for the study of cell-autonomous functions.
|
29051386 |
2017 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma development is dependent on loss of p53 and potentiated by loss of pRb, revealing a dominance of p53 mutation in the development of osteosarcoma.
|
18559481 |
2008 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma cells (U2OSp53DD) that are deficient in p53 and lack the G1 cell cycle checkpoint respond to AAV infection through a transient G2 arrest.
|
21853057 |
2011 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
Osteosarcoma cell lines with no detectable alteration of the p53 gene contained abundant p53 transcripts.
|
2253237 |
1990 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Osteosarcoma is associated with massive genomic instability, making it problematic to identify driver genes using human tumors or prototypical mouse models, many of which involve loss of Trp53 function.
|
25961939 |
2015 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
Tumor protein p53 (TP53), mitogen-activated protein kinase 1 (MAPK1) and estrogen receptor 1 (ESR1) were identified the most important osteosarcoma‑associated genes, with the highest levels of topological properties.
|
28259906 |
2017 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 structural rearrangements have been previously reported in a significant subset of osteosarcomas, where they result in loss of p53 protein expression by immunohistochemistry.
|
31216325 |
2019 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations were detected in 12 cases (five osteosarcomas, four MFHs, and three leiomyosarcomas), of which none showed amplification, but one had increased levels of MDM2 mRNA.
|
8064888 |
1994 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
TP53 mutations appear in codons most frequently mutated in osteosarcomas.
|
9559293 |
1997 |
Osteosarcoma
|
1.000 |
GermlineCausalMutation
|
disease |
ORPHANET |
A germ-line p53 mutation was detected in one of these patients, and a further rearrangement of the residual wild-type allele was detected in tumor tissue. p53 germ-line mutations can contribute to the enhanced predisposition to tumor development manifest in patients with multifocal osteosarcoma.
|
1349175 |
1992 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
A polysaccharide from Enterobacter cloacae induces apoptosis of human osteosarcoma cells through the activation of p53 and mitochondrial intrinsic pathway.
|
30336239 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
A rearranged signal was found in 20/37 cases (54%) of OS and in none of the other sarcomas or benign bone lesions, giving the FISH test 100% specificity for a diagnosis of OS. p53 immunostaining was generally not predictive of the results obtained by FISH and could not substitute for this test.
|
29543677 |
2018 |
Osteosarcoma
|
1.000 |
GeneticVariation
|
disease |
BEFREE |
A similar proportion of localized osteosarcomas had alterations of the p53 gene (55 of 247 specimens; 22.3%) compared with tumors from patients who had metastases at the time of diagnosis (5 of 25 specimens; 20%; P = 0.96).
|
11596036 |
2001 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Aberrant expression of the transcription factor, runt-related transcription factor 2 (RUNX2), is a key pathological feature in osteosarcoma and associated with loss of p53 and miR-34 expression.
|
30637720 |
2019 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
According to our findings AgNPs are able to kill osteosarcoma cells independently from their actual p53 status and induce p53-independent cancer cell apoptosis.
|
27291325 |
2016 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.
|
16211088 |
2006 |
Osteosarcoma
|
1.000 |
Biomarker
|
disease |
BEFREE |
Adp14ARF infection of U2OS osteosarcoma cells which has wild type p53 and mutant p14ARF revealed high levels of p14 (ARF) expression within 24h.
|
15207713 |
2004 |
Osteosarcoma
|
1.000 |
AlteredExpression
|
disease |
BEFREE |
After SOX4 gene silencing, the protein expression levels of Bax, Caspase-3, and P53 in osteosarcoma cells were significantly elevated, while the protein expression levels of Bcl-2, MMP2, and MMP9 were obviously decreased.
|
29038881 |
2018 |